盐酸度洛西汀肠溶胶囊在中国健康人体内的药动学研究

张毕奎;徐萍;朱运贵;向大雄;陈本美;冯胜;宋娟;谢志红;马宁;李焕德

中国药学杂志 ›› 2008, Vol. 43 ›› Issue (07) : 527-531.

中国药学杂志 ›› 2008, Vol. 43 ›› Issue (07) : 527-531.
论著

盐酸度洛西汀肠溶胶囊在中国健康人体内的药动学研究

  • 张毕奎,;徐萍,;朱运贵,;向大雄,;陈本美;冯胜;宋娟;谢志红;马宁;李焕德,
作者信息 +

Pharmacokinetics of Duloxetine Enteric-Capsules in Healthy Chinese Volunteers

  • ZHANG Bi-kui1,2, XU Ping2,3, ZHU Yun-gui2,3, XIANG Da-xiong2,3, CHEN Ben-mei4, FENG Sheng5, SONG Juan3, XIE Zhi-hong3, MA Ning3, LI Huan-de2,3
Author information +
文章历史 +

摘要

目的研究盐酸度洛西汀肠溶胶囊的药动学,为该药的临床应用提供依据。方法分单剂量组和多剂量组进行试验。单剂量组分周期交叉口服高、中、低剂量受试药物,多剂量组按临床常规剂量连续给药7d。采用HPLC-MS测定血浆中度洛西汀的浓度,用DAS2.0对血药浓度-时间数据进行药动学模型拟合和参数计算。结果体内药动学符合一室模型特征。主要药动学参数ρmax,AUC0-72,AUC0-∞与剂量相关,tmax,t1/2则与剂量无关。连续口服盐酸度洛西汀肠溶胶囊,4d后血药浓度达到稳态。除单剂量组口服44.8mg时的Ka值外,主要药动学参数性别间均没有差异。结论盐酸度洛西汀在健康人体内符合线性药动学特征,主要药动学参数没有性别差异。

Abstract

OBJECTIVE To determine the pharmacokinetics of duloxetine and to provide evidence for its clinical application.METHODS The experiment consisted of 2 groups:a single-dose group and a multi-dose group.High,middle and low doses were given orally to each volunteer in turns during different periods in the single-dose group.A clinical routine dose was given to each volunteer in the multi-dose group for 7 d continuously.The plasma concentration of duloxetine was determined by HPLC-MS.Then DAS 2.0 software package was used to fit the plasma concentration-time data and to calculate the parameters.RESULTS The pharmacokinetic profiles were discribed by an one-compartment model.ρmax,AUC0-72,and AUC0-∞ were correlated to the doses,but no tmax and t1/2.Steady state concentration was reached 4 d after the continuous oral administration of duloxetine enteric-capsules.Except for the Ka value after the single oral dose of 44.8 mg duloxetine,there was no gender difference in other pharmacokinetic parameters.CONCLUSION Duloxetine was linearly correlated to the doses in the plasma of healthy volunteers and no gender difference was found in the main pharmacokinetic parameters.

关键词

度洛西汀 / 肠溶胶囊 / 药动学 / 高效液相色谱-质谱联用

Key words

duloxetine / enteric-capsule / pharmacokinetics / HPLC-MS

引用本文

导出引用
张毕奎;徐萍;朱运贵;向大雄;陈本美;冯胜;宋娟;谢志红;马宁;李焕德 . 盐酸度洛西汀肠溶胶囊在中国健康人体内的药动学研究[J]. 中国药学杂志, 2008, 43(07): 527-531
ZHNG i-kui;XU Ping;ZHU Yun-gui;XING D-xiong;CHEN en-mei;FENG Sheng;SONG Jun;XIE Zhi-hong;M Ning;LI Hun-de;. Pharmacokinetics of Duloxetine Enteric-Capsules in Healthy Chinese Volunteers [J]. Chinese Pharmaceutical Journal, 2008, 43(07): 527-531

参考文献

[1] HUNZIKER M E, SUEHS B T, BETTINGER T L, et al. Duloxetine hydrochloride: A new dual-acting medication for the treatment of major depressive disorder[J] .Clin Ther,2005, 27(8):1126-1143. [2] LANTZ R J, GILLESPIE T A, RASH T J,et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects[J] .Drug Metab Dispos,2003, 31(9):1142-1150. [3] SURI A, REDDY S, GONZALES C,et al.Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects[J] .Int J Clin Pharmacol Ther,2005 , 43(2):78-84. [4] SHARMA A, GOLDBERG M J, CERIMELE B J,et al. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor[J] .J Clin Pharmacol,2000, 40(2):161-167. [5] SKINNER M H, KUAN H Y, SKERJANEC A, et al. Effect of age on the pharmacokinetics of duloxetine in women[J] .Br J Clin Pharmacol,2004 , 57(1):54-61.

Accesses

Citation

Detail

段落导航
相关文章

/